Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 3/1/1990


1.		Phase II Study of LY186641 (a Sulfonylurea) in Patients with Advanced and/or Metastatic Carcinoma of the Pancreas (Summary Last Modified 03/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				19 to 75								UNMC-38089 NCI-V89-0270

Last Modified: 8/1/1990


2.		Phase II Study of LY186641 in Patients with Metastatic or Locally Recurrent Renal Cell Carcinoma (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18								CAN-NCIC-IND46 NCI-V90-0028, IND46

Last Modified: 2/1/1990


3.		Phase II Study of LY186641 (a Sulfonylurea) Administered Daily for 14 Days in Patients with Advanced, Recurrent, or Metastatic Breast Cancer (Summary Last Modified 02/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75								GUMC-18289 NCI-V89-0277

Last Modified: 7/1/1990


4.		Phase II Study of LY186641 in Patients with Extensive Small Cell Lung Cancer (Summary Last Modified 07/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								CAN-NCIC-IND47 NCI-V90-0029, IND47

Last Modified: 8/1/1990


5.		Phase II Study of LY186641 for Patients with Advanced (Stage IIIB or IV) or Recurrent non-Small Cell Lung Cancer (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75								MDA-DM-89030 NCI-V90-0014

Last Modified: 6/1/1990


6.		Phase II Study of LY186641 in Patients with Refractory Epithelial Carcinoma of the Ovary (Summary Last Modified 06/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to physiologic 70								MDA-ID-89012 NCI-V89-0251

Last Modified: 9/1/1990


7.		Phase II Study of LY186641 (a Sulfonylurea) in Patients with Locally Advanced and/or Metastatic Carcinoma of the Pancreas (Summary Last Modified 09/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75								GUMC-690 NCI-V90-0121

Last Modified: 11/1/1993


8.		Phase I Study of Sulofenur (LY186641) in Pediatric Patients with Refractory Solid Tumors (Summary Last Modified 11/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				under 21 at diagnosis				NCI				SJCRH-LY-SUL NCI-T91-0172D, T91-0172

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute